Enterprise Value
78.76M
Cash
24.22M
Avg Qtr Burn
-5.71M
Short % of Float
4.88%
Insider Ownership
2.88%
Institutional Own.
13.07%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) Details Liver Dominant metastatic Ocular Melanoma Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
CHEMOSAT® Details Uveal melanoma | Phase 2 Data readout | |
HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) Details Intrahepatic cholangiocarcinoma | Failed Discontinued |